| Description |
Micrococcin P1 is a macrocyclic peptide antibiotic and is a potent hepatitis C virus (HCV) inhibitor with an EC50 range of 0.1-0.5 μM[1]. Micrococcin P1 has in vitro antibacterial activity against Gram-positive bacterial strains. The MIC values of Micrococcin P1 against S. aureus 1974149, E. faecalis 1674621 and S. pyogenes 1744264 are 2 μg/mL, 1 μg/mL and 1 μg/mL, respectively[2]. Micrococcin P1 is also a potent inhibitor of the malaria parasite Plasmodium falciparum[3].
|
| Related Catalog |
|
| Target |
HCV[1]; Bacterial[2]; Parasite[3]
|
| In Vitro |
Dose-response assays reveales Micrococcin P1 to be very potent with a minimal inhibitory concentration (MIC) of 32-63 nM. Cytotoxicity assays reveales no significant impairment on cell line growth (<10% inhibition at 30 mM) over a 40 h period for both the hepatic cell line HepG2 and the monocytic cell line THP-1, leading to a selectivity index greater than 500. Also investigats the intracellular activity of Micrococcin P1, it is active against GFP-expressing M. tuberculosis H37Rv growing inside RAW 264.7 macrophages with an IC80 of about 1 mM with potency comparable with that of isoniazid[1].
|
| References |
[1]. Lee M, et al. Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner. Antiviral Res. 2016 Aug;132:287-95. [2]. Akasapu S, et al. Total synthesis of micrococcin P1 and thiocillin I enabled by Mo(vi) catalyst. Chem Sci. 2018 Dec 3;10(7):1971-1975. [3]. Carnio MC, et al. Pyridinyl polythiazole class peptide antibiotic micrococcin P1, secreted by foodborne Staphylococcus equorum WS2733, is biosynthesized nonribosomally. Eur J Biochem. 2001 Dec;268(24):6390-401.
|
